J&J's Rising Pharmaceutical Sales Hurt by Strong U.S. Dollar

(Bloomberg) -- Johnson & Johnson recorded 20 percent growth in its drug unit in the second quarter, but the company is trimming its forecast for the year as a strong dollar hampers its growth.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.